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Abstract 
The number of clinical trials involving implants for trauma and orthopedic surgery is increasing. 
The International Conference of Harmonization-Good Clinical Practice (ICH-GCP) guideline 
has been developed in order to assure that the rights, safety, and well-being of trial subjects (i.e., 
patients) are protected. Not performing a trial according to legal requirements including this 
guideline is no longer acceptable, and trial audits are increasingly being performed as an 
independent quality check for data validity and credibility. This manuscript provides an 
overview of the Guideline for Good Clinical Practice in the context of conducting an implant 
trial in trauma and orthopedic surgery. As long as all guidelines are adequately adhered to and all 
paperwork is in order, there is no reason to fear a trial audit. 
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I. THE PRINCIPLES OF ICH-GCP 
The ICH-GCP guideline, which has its origin in the Declaration of Helsinki, is an international 
ethical and scientific quality standard for the design, conduct, recording, and reporting of trials 
involving human subjects (2, 3). The guideline provides a unified standard for clinical research 
in the European Union, Japan and the United States, in order to facilitate mutual acceptance of 
clinical data by regulatory authorities in these jurisdictions. 
The key principle of the ICH-GCP guideline is the ethical conduct of a trial (2). No trial 
can be initiated before all foreseeable risks and inconveniences are weighted against the 
anticipated benefit for the individual trial subject and society. The safety and well-being of the 
trial subjects should always prevail over scientific interest (2). Medical device GCP includes the 
following key items: (1) Appropriate clinical trial documentation as defined by ICH-GCP; (2) 
Medical Ethics Committee approval of the trial; (3) Ethics committee supervision and review of 
amendments and adverse events; (4) Written clinical trial study report about the study outcome. 
If applicable, competent authority approval should also be obtained. 
 
II. DESIGNING THE TRIAL AND WRITING THE STUDY PROTOCOL 
Clinical trials should be scientifically sound, and described in a clear, detailed protocol (2). The 
protocol should provide detailed information on the rationale, aims, objectives, design, proposed 
analyses, methodologies, data analyses, and conduct of the trial. Table 1 provides an overview of 
key topics to be mentioned in the protocol. Local authorities may also require that the applicable 
ethics issues are adequately addressed in the protocol. 
All relevant literature related to the efficacy and safety of the implant should be 
summarized in the protocol. The best approach for assessing available literature data is by 
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performing a systematic review and/or meta-analysis. Commonly used electronic databases 
include MEDLINE, EMBASE and CINAHL. Depending on the topic, recent systematic reviews 
may already be available in the Cochrane library. The conduct of a meta-analysis helps to 
systematically appraise the available evidence, and will provide guidance in formulating a 
testable research question for the trial. 
In surgical study protocols attention should also be paid to surgeon related aspects. The 
individual skills and habits of the orthopedic trauma surgeon participating in a clinical trial may 
influence the outcome of the trial. Therefore, it may be important to standardize key elements of 
the intervention for both the treatment group(s) and the control group in order to reduce bias due 
to variation in techniques and skills of participating surgeons.  
There are several options for reducing technique-associated bias, each with related 
advantages and disadvantages. These options include: (1) all surgeries are being done by the 
same surgeon; (2) obliged teaching sessions prior to the trial; (3) auditing surgical performance 
throughout the trial; and (4) stratifying patients by surgeon at the time of randomization. For 
specific interventions it may also be better to determine a priori how may procedures each 
participating surgeon should have performed in his/her entire career and/or in the last year prior 
to trial startup. 
Similar to the standardization of surgical and technique associated factors, guidelines 
regarding peri-operative care (e.g., thromboprophylaxis, antibiotic prophylaxis, optimization for 
surgery, pain medication) and after-treatment (e.g., physical therapy) should be specified in the 
protocol if relevant for the trial. 
Availability of experienced surgeons is critical when it comes to the ability to enroll 
patients at any time. Any site participating in a trial should have a team with adequate skills, 
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expertise and equipment available for participation. Trials involving acute traumatic injuries may 
require the prompt availability of a skilled surgical team. 
Other key aspects of a methodologically sound study design are randomization, allocation 
concealment, and blinding (4-8). Randomization ensures that both known and unknown 
prognostic factors are equally distributed in the treatment and control group. Allocation 
concealment prevents undermining of random, unpredictable assignment sequences resulting in 
overestimated treatment effects (4, 8). In surgical trials, blinding of patients and surgeons may 
not be feasible. Blinding of outcome assessors should be aimed at as much as possible, as 
treatment effects are known to be over-estimated in unblinded studies (4, 7, 9, 10). If applicable, 
one might consider blinding of radiographs by superimposing the implants used in either trial 
arm (11). Blinding of the surgical site could be achieved by covering it with the same band-aid, 
regardless of the intervention.  
It is becoming more common to publishing the trial protocol prior to or immediately 
following trial startup. Early publishing of the trial protocol may lead to higher protocol 
adherence, and at the same time may set a higher threshold for any post-hoc protocol revisions 
and amendments. In the future, more scientific journals may also request submission of the trial 
protocol together with the final manuscript in order to identify protocol deviations.  
 
III. ETHICS APPROVAL AND TRIAL REGISTRATION 
Clinical trials are closely supervised by legal authorities. All clinical trials that involve an 
intervention on patients must be approved by a supervising ethics review committee before 
permission is granted to run the trial. After receiving this permission, the trial should be 
conducted in compliance with ICH-GCP, strictly following the study protocol. 
 6 
 An ethics review committee is an independent body of medical professionals, and lay 
members. Usually this committee is called a medical research ethics committee (MREC or EC), 
or Institutional Review Board (IRB) for the US. An independent ethics committee can be 
consulted if the local investigator's hospital or institution has no MREC or IRB. The legal status, 
constitution, and responsibilities of ethics committees may differ from country to country. 
The mandate of the ethics review committee is to safeguard the rights, safety, and well-
being of all research participants. Ethics committees review the study protocol, the case report 
forms, the study budget and trial participant payment, the consent form, and any other study 
documentation in order to ensure that the trial is justified, safe, that the patients are properly 
informed about the research, and that adequate facilities and resources are available. Table 2 
provides an overview of trial documents to be reviewed by the ethics committee. They may 
request changes in study procedures or in the explanations given to the patient (e.g., patient 
information brochure or consent form). 
In the US and most European countries, the local ethics review committee must certify 
that site (principal) investigators and their staff have adequate knowledge on ICH-GCP before 
they can conduct clinical trials. Attending an ICH-GCP course is often compulsory for the 
principal investigator.  
 For multicenter trials, one MREC or IRB will act as primary, central ethics review 
committee. They perform a full review of the study documents and should approve the trial prior 
to its startup. Local MRECs or IRBs should only advice on feasibility of the trial at that 
particular site. International trials require a central ethics review committee in every participating 
country. 
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Once the trial has been approved by the ethics review committee, it is necessary to 
continue to communicate regularly with the MREC or IRB. Investigators are obliged to submit 
an annual update report on the progress of the study and any new safety information related to 
the study. Also, all amendments to the protocol, consent form, and case report forms must be 
promptly reported. Amended documents cannot be implemented before approval of the ethics 
review committee has been obtained.  
In addition to ethics approval, legislation in some countries requires registration of trials 
in a public trial register. An overview of primary registries that meet the requirements of the 
International Committee on Medical Journal Editors (ICMJE) is given in Table 3. 
 
IV. INFORMED CONSENT AND RECRUITMENT 
Ensuring informed consent from the participants is a major cornerstone of ethical human subject 
research. In compliance with ICH-GCP guidelines, every trial subject should give his/her 
informed consent prior to clinical trial participation (3). Consent is considered 'informed' when 
given by a person who understands the purpose and the nature of research, what is required from 
the participant and what may be the potential benefits and risks resulting from the study. If the 
patient is unable to consent for him/herself, researchers can seek consent from the patient's 
legally authorized representative. Who is entitled to act as legal representative may differ 
between countries, depending on local legislation. 
If limited numbers of trial subjects are to be expected at a single site, it may be preferable 
to choose for a multicenter approach, thereby reducing the time needed for trial subject 
enrolment. As a consequence, the process of obtaining MREC or IRB approval will take more 
time to complete, as local feasibility of the trial needs to be tested by a local ethics review 
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committee at each participating site. 
 
V. ADVERSE EVENT REPORTING 
If during the trial an adverse event is encountered, this should be reported to the local MREC or 
IRB. An adverse event is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a trial-specific product (e.g., implant, medical device or 
pharmaceutical product) and which does not necessarily have a causal relationship with this 
treatment. (3). A serious adverse event is an adverse event which results in death, is life-
threatening, requires in-patients hospitalization (or prolongs existing hospitalization), results in 
persistent or significant disability of incapacity, or is a congenital anomaly or birth defect (3). A 
non-serious adverse event is any adverse event that does not meet the criteria of a serious adverse 
event. Many review boards require serious adverse events to be reported within 24 hours and 
non-serious adverse events to be reported within 48 hours, in compliance with ICH-GCP 
guidelines. If applicable, adverse events should also be reported to the data safety and monitoring 
board. 
 
VI. THE RESEARCH TEAM 
The medical care given to, and medical decisions made on behalf of trial subjects should always 
be the responsibility of a qualified physician (3). However, the overall conduct of the trial and 
the trial-related activities may involve a dedicated research team. Each individual in this team 
should be qualified by education, training, and experience to perform his or her respective tasks 
(3). A single center trial requires a different team than a large, international trial involving 
multiple sites per country. Multicenter trials usually have a central project office or methods 
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center that coordinates and overseas the trial. Requirements and responsibilities of key persons 
and groups within the team are given below. 
 
A. Site Principal Investigators and Site Investigators 
If a participating clinical site has more than one surgeon enrolling patients into the trial, one 
investigator from each site should be designated as the site principal investigator (PI). The PI is 
the medical practitioner or licensed medically qualified person conducting the study in 
accordance with the protocol. The site PI serves as the primary contact for the sponsor or central 
methods center, and is responsible for all communication with the local MREC or IRB. The site 
PI should also ensure correct documentation in case report forms and patient hospital records to 
enable source data verification. In multicenter trials, the site PI also attends investigator meetings 
and conference calls regarding the trial. 
A site PI may appoint any number of co-investigators who are given the responsibility to 
actually conduct the trial as defined in the clinical investigation plan. The site investigators are 
responsible for enrolling patients into the trial, following the study protocol, and following 
patients according to the study protocol. 
In addition to the site investigators, the site PI may also appoint a dedicated clinical 
research coordinator to manage the day-to-day trial activities at the clinical sites. These include 
regular communication with the local ethics committee, assisting with the patient enrolment, 
completing case report forms, scheduling patient follow-up appointments, and entering data into 
a database or submitting data to the central methods center. The clinical research coordinator and 
the site PI work closely together to ensure compliance and data quality. 
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B. Sponsor 
The sponsor is the organization that has initiated the trial. This could be a medical industrial 
company or a hospital. The sponsor and the local site PIs are jointly responsible for writing a 
site-specific patient information brochure and informed consent form that accurately informs the 
potential subjects about the true risks and potential benefits of participating in the study, while at 
the same time presenting the material as briefly as possible and in ordinary language. 
Throughout the clinical trial, the sponsor is responsible for: (1) accurately informing the 
local site (principal) investigators about any relevant news on the trial; (2) monitoring the results 
of the study as they come in from the various sites, as the trial proceeds; and (3) collecting 
adverse event reports from all site investigators in the study, and for informing all the 
investigators of the sponsor's judgment as to whether or not these adverse events were related to 
the study treatment. 
 
C. Steering Committee 
The sponsor may appoint a Steering Committee that will be responsible for the overall design 
and conduct of a trial. This committee consists of the principal investigator(s), the biostatistician 
and trial methodologist, and other key investigators. It communicates with the Data Monitoring 
Committee, the Central Adjudication Committee, and the site PIs. At the completion of the trial, 
the Steering Committee maintains responsibility for the final data analysis and publication (12). 
 
D. Data monitoring committee (DMC) 
In larger clinical trials, a sponsor will use the services of a DMC, known in the U.S. as a Data 
Safety Monitoring Board (12). This is an independent group of health care professionals who are 
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completely independent of the investigators and who have no financial, scientific, or other 
conflict of interest with the trial. The DMC members should have adequate expertise in clinical 
trial methodology, biostatistics, and regulatory guidelines like ICH-GCP. The DMC reviews 
unblinded data related to the conduct of the study (e.g., recruitment rates, non-compliance, and 
protocol violations), carries out evaluations of serious unanticipated adverse events, evaluates 
pre-planned interim analyses for efficacy, safety, and the triggering of statistical warning rules. 
The DMC has the power to recommend termination of the study based on their review. 
 
E. Central Adjudication Committee (CAC) 
The CAC is designated to review important study end-points reported by the trial investigators to 
determine if they meet protocol-specified criteria. Site investigators should provide them with all 
relevant information such as X-rays, surgical reports, and clinical notes. If feasible, the CAC 
should be blinded to treatment allocation where ever possible in order to reduce bias and random 
error in determining outcome events (4, 7, 12). This committee is optional and can be beneficial 
in surgical trials, in which the intervention(s) cannot be blinded. 
 
VII. DATA MANAGEMENT AND TRIAL MONITORING 
Following initiation of a clinical trial, progress and quality of the collected data should be 
monitored in detail. The purposes of clinical trial monitoring is to verify that the rights and well-
being of human subjects are protected, to verify that the reported clinical trial data are accurate, 
complete, and verifiable from source documents, and to verify that the conduct of the trial is in 
compliance with the currently approved protocol/amendment(s), with ICH-GCP, and with the 
applicable regulatory requirement(s). 
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Although the sponsor holds the overall responsibility of the trial, it is the responsibility of 
the site PI and the site investigator(s) to provide complete and high-quality data. A sponsor may 
appoint monitors to oversee the conduct of the trial or hire a Contract Research Organization 
(CRO) for that purpose. The monitor continuously conducts the in-process quality control for the 
trial, checks the performance of the trial and its compliance with the overall legal requirements 
and ICH-GCP. The monitor represents the sponsor, periodically visits the trial sites and reviews 
the data through source data verification (i.e., reviewing the collected data against the medical 
records and reports pertaining to the trial subject). 
ICH-GCP guidelines dictate that all clinical trial information should be recorded, 
handled, and stored in a way that allows its accurate reporting, interpretation and verification (3). 
All data concerning a trial participant should be stored in a folder, in which each document 
should have the subject’s unique identifier. In compliance with regulatory requirements 
regarding privacy and confidentiality protection, subjects should be given a unique identification 
number (3). A common numbering system is a combination of the trial acronym (or protocol 
number), followed by the site number and subject number. 
Data collection may be challenging, both in single as in multicenter trials. Coordinating 
centers increasingly use centralized computer data collection systems that can be fax-based or 
Internet-based (1, 13). Data should be checked for missing information, implausible data, and 
inconsistencies at an early stage. Any problem encountered should be corrected as early as 
possible. This is primarily the task of the local research coordinator. Failure to resolve problems 
urgently will violate the ICH-GCP guideline and can result in termination of the trial by the 
authorities as a worst-case scenario. 
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VIII. REGULATORY DEVICE TRIALS 
Regulatory device trials allow for the clinical evaluation of (new) medical devices, determining 
whether or not they can be safely and effectively used in patient care (14).  
In the US, the Food and Drug Administration (FDA) must give approval to all clinical 
trials involving new medical devices that pose a significant risk to patients. Depending on the 
assigned level of risk (i.e., class I, II, III), a clinical trial involving an approved medical device 
for a new indication not covered by the initial marketing approval may also require FDA 
approval (15). In the EU, all medical devices must be identified with the CE (Conformité 
Européenne; in English European Conformity) mark. There are numerous 'Agreements on 
Mutual Recognition of Conformity Assessment' between the EU and other countries such as the 
USA, Japan, Canada, Australia, New Zealand and Israel. Regulatory trials must function in 
compliance with governmental regulations. Legislation may vary considerably between 
countries. 
Participation in a regulatory trial is more complex and time-intensive than participating in 
a non-regulatory trial. Regulatory trials require an even stricter adherence to ICH-GCP. In 
practice, the administrative workload will be higher and details must be recorded, sometimes to 
the extreme. 
 
IX. TRIAL AUDITING 
Following in-process quality checks by a trial monitor or DMC, auditing or inspection is the 
second line of defense for trial compliance. The ICH-GCP guideline defines an audit as a 
systematic and independent examination of trial-related activities and documents for industry-
sponsored trials. An audit can be requested by the sponsor, but also by formal bodies such as the 
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ethics committee. The aim of the audit is to ensure that trials are conducted in compliance with 
the trial protocol, the sponsor’s standard operating procedures, and all applicable guidelines and 
regulatory requirements. In other words, auditing is critical in ensuring that the collected data is 
credible and reliable. Audits are conducted at the time of screening, halfway during the trial and 
at the trial closure. 
Clinical trial audits are performed by regulatory authorities, trial sponsors, or 
organizations nominated by the trial sponsor (3). The regulatory authorities in the United States 
and European Union perform audits of the sponsor, manufacturing plants, and study sites. Study 
sites always receive advanced written notification of an audit, allowing them sufficient time to 
prepare for the audit. Auditing uses a structured agenda and clearly defined objectives. The 
auditor will provide a checklist of documents and data that should be available, along with a list 
of persons to be present during the audit. 
Any issues identified that could result in major non-compliances should be properly 
addressed by the site PI immediately after they have been identified. Negative audit findings may 
vary in severity from deficiencies in essential trial documentation that can easily be rectified, to 
errors in consent procedures and investigator fraud. Serious discrepancies may lead to 
termination of a trial at a study site or legal proceedings against an investigator. 
As audits can be very stressful for investigators, they need to be thoroughly prepared. 
Organizing training sessions or pre-investigational site visits may reveal any problems that might 
be encountered during the actual audit, and will enable the site PI the chance of a timely solution. 
As long as all members of the research team conduct the trial in agreement with ICH-GCP 
guidelines and other regulatory requirements, they have nothing to fear. 
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Table 1. Content of the trial protocol 
 
 Title of the project 
 Names, qualifications and addresses of the sponsor (i.e., trial initiator) 
 Justification and rationale of the trial, including literature overview 
 Objectives of the trial, including testable hypothesis 
 Inclusion and exclusion criteria 
 Details on randomization, blinding and treatment allocation 
 Definition of the interventional procedures 
 Details on the implant tested 
 Anticipated adverse events and related risks associated with the implant 
 Definition of perioperative care, after-treatment and any other trial-specific treatments* 
 Detailed overview of outcome assessment, including justification 
 Detailed list of data to be collected, including procedures how to collect these 
 Required sample size, including statistical justification 
 Definition of statistical methodologies to be applied 
 Details on handling and storage of data and documents 
 Details on public disclosure and publication 
 Detailed list of literature references 
* Only if applicable 
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Table 2. Overview of trial documents to be reviewed by the ethics committee 
 
 Application form, including names and qualifications of participating surgeons 
 Study protocol 
 Investigational brochure and other documentation related to the trial (e.g., Standard Operations 
Manual)* 
 Information sheet for research participants 
 Consent Form for research participants and/or their legal representative 
 Data collection booklets/Case Report Forms/questionnaires 
 Promotion material (i.e. study posters or pocket cards) 
 Details on radiology and/or toxicology safety 
 Details on payment to trial participants 
 Letters of agreement and/or contract with sponsor* 
 Up-to-date, dated and signed Curriculum vitae (CV) of the principal investigator, all co-
investigators and independent physician 
 Trial termination criteria* 
* Only if applicable 
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Table 3. Primary Registries in the WHO Registry Network 
 
Registry Website 
Australian New Zealand Clinical Trials Registry  
(ANZCTR) 
http://www.anzctr.org.au/ 
Chinese Clinical Trial Register (ChiCTR) http://www.chictr.org/ 
Clinical Trials Registry - India (CTRI) http://www.ctri.in/Clinicaltrials/index.jsp 
German Clinical Trials Register (DRKS) http://www.germanctr.de/ 
Iranian Registry of Clinical Trials (IRCT) http://www.irct.ir/ 
ISRCTN.org http://www.isrctn.org/ 
Japan Primary Registries Network (JPRN) http://www.isrctn.org/ 
The Netherlands National Trial Register (NTR)  http://www.trialregister.nl/trialreg/index.asp 
Pan African Clinical Trial Registry (PACTR) http://www.pactr.org/ 
Sri Lanka Clinical Trials Registry (SLCTR)  http://www.slctr.lk/ 
Primary registries in the WHO Registry Network meet specific criteria for content, quality and 
validity, accessibility, unique identification, technical capacity and administration. Primary 
Registries meet the requirements of the ICMJE (International Committee on Medical Journal 
Editors) are listed, along with their websites. 
(Source: http://www.who.int/ictrp/network/primary/en/index.html). 
